Sangart, Inc. Initiates Phase III Clinical Trials
- Category: Proteins and Peptides
- Published on Wednesday, 14 February 2007 02:00
- Hits: 2247
SAN DIEGO, CA, USA | Feb 13, 2007 | Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, announced today that it has begun enrolling patients in two parallel European Phase III trials on Hemospan®, its lead drug candidate. Hemospan is the first oxygen therapeutic specifically engineered to target oxygen delivery to tissues.
The studies will be conducted by clinicians at up to 36 academic medical centers in the United Kingdom, Sweden, the Netherlands, Belgium, Poland and the Czech Republic. More than 800 elective orthopedic surgery patients will be enrolled in the studies, which are designed to gauge the ability of Hemospan® to prevent and treat hemodynamic instability, especially hypotension, or low blood pressure, during their operations. The goal is to determine if Hemospan® can help patients avoid hypotension during elective surgery. Hypotension is one of the key indicators for blood transfusion in such patients.
No similar therapeutic agents are currently on the market in Europe or the U.S. Research has shown that Hemospan’s novel oxygen delivery mechanism may provide a safe and effective alternative to blood transfusions, which are becoming more common worldwide despite the increased safety concerns in many developing countries.
Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as alternatives to blood transfusions.
Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. The counterintuitive discoveries by Dr. Winslow’s group on the effective action of oxygen transport agents have been patented and published in numerous scientific articles. From this experience, Sangart’s lead product, Hemospan®, was designed using unique polyethylene glycol conjugation to create a hemoglobin-based product that is intended to serve as an alternative to donated blood.
The key breakthroughs in the development of Hemospan® were the understanding of the mechanisms of vasoconstriction and the development of simplified production methods that are designed to make the final product commercially viable. These breakthroughs laid the groundwork for Sangart’s business concept of developing cost-effective oxygen carriers that can be used in lieu of transfused red blood cells during episodes of temporary blood loss, such as surgery or trauma.
To learn more about Sangart, please visit the company’s website at www.sangart.com.